Fabry Disease Market Report by 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast

Some of the key facts of the Fabry Disease Market Report: 

• The Fabry Disease market size was valued approximately USD 1,167.8 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• By aggregating the instances in the various nations, the total prevalence cases in the 7MM were determined. There were 13,053 Fabry Disease cases in the 7MM population overall in 2020, with the majority of those cases being found in the US. In contrast to Japan, which had 437 instances in 2020, the EU5 countries had 4,708 cases
• Germany had the most Fabry Disease cases per 100,000 people among the EU5 nations in 2020 (1,158 cases). These are anticipated to increase by 2032, according to DelveInsight’s projections
• In the US, males were more likely than females to have Fabry disease. 4,099 males and 3,809 females were affected by Fabry disease in 2020. According to DelveInsight, the number will rise by 2032
• Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others
• Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
• The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States
• The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

Fabry Disease Overview

Alpha-galactosidase A (-Gal A), a lysosomal storage disorder that is hereditary, is the primary culprit in Fabry disease. The accumulation of enzyme substrates (Gb3 and lyso-Gb3) caused by decreased -Gal A activity in lysosomes leads to cellular damage in tissues all over the body.

Get a Free sample for the Fabry Disease Market Report 

https://www.delveinsight.com/report-store/fabry-disease-market

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Fabry Disease
• Prevalent Cases of Fabry Disease by severity
• Gender-specific Prevalence of Fabry Disease
• Diagnosed Cases of Episodic and Chronic Fabry Disease

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fabry Disease Therapies and Key Companies

• PRX-102: Protalix Biotherapeutics
• AVR-RD-01: AVROBIO
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: Greenovation Biotech GMBH
• PRX-102: ICON plc
• pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.
• migalastat: Amicus Therapeutics
• Agalsidase alfa: Shire

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market

Fabry Disease Market Strengths

• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease.
• Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations.
• Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy.

Fabry Disease Market Unmet Needs

• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Fabry Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others
• Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
• Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement 

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease 

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2019–2032)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17.  Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services